Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor

American Journal of Pathology

Volumn 167, Issue 3, 2005, Pages 879-885

  Köbel, Martin ^a,b   Pohl, Gudrun ^a   Schmitt, Wolfgang D ^b   Hauptmann, Steffen ^b   Wang, Tian Li ^a   Shih, Ie Ming ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HLA G ANTIGEN; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PD 59089; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER INVASION; CELL MOTILITY; CELL PROLIFERATION; CHORIOCARCINOMA; CONTROLLED STUDY; CYTOTROPHOBLAST; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MICROSCOPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNCYTIOTROPHOBLAST; TROPHOBLAST; TROPHOBLASTIC TUMOR; WESTERN BLOTTING;

EID: 24044449248     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62059-7     Document Type: Article

References (47)

1. Shih IM, Kurman RJ: The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001, 20:31-47
2. Shih I-M, Mazur MT, Kurman RJ: Gestational trophoblastic disease. Blaustein's Pathology of the Female Genital Tract. Edited by Kurman RJ. New York, Springer-Verlag, 2002, pp 1193-1247
3. Oldt III RJ, Kurman RJ, Shih IM: Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin. Am J Pathol 2002, 161:1033-1037
4. Shih IM, Kurman RJ: p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol 2004, 28:1177-1183
5. Shih I-M, Kurman RJ: Molecular basis of gestational trophoblastic diseases. Curr Mol Med 2002, 2:1-12
6. Sebolt-Leopold JS: MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004, 10:1907-1914
7. Holmstrom TH, Tran SE, Johnson VL, Ahn NG, Chow SC, Eriksson JE: Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis. Mol Cell Biol 1999, 19:5991-6002
8. Cowley GP, Smith ME: Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer 1995, 60:325-329
9. Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell Sci 2004, 117:4619-4628
10. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA: Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998, 140:1255-1263
11. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265:966-970
12. Mansour SJ, Resing KA, Candi JM, Hermann AS, Gloor JW, Herskind KR, Wartmann M, Davis RJ, Ahn NG: Mitogen-activated protein (MAP) kinase phosphorylation of MAP kinase kinase: determination of phosphorylation sites by mass spectrometry and site-directed mutagenesis. J Biochem (Tokyo) 1994, 116:304-314
13. Anand-Apte B, Zetter BR, Viswanathan A, Qiu RG, Chen J, Ruggieri R, Symons M: Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. J Biol Chem 1997, 272:30688-30692
14. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997, 137:481-492
15. Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF: FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004, 6:154-161
16. Cheresh DA, Leng J, Klemke RL: Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol 1999, 146:1107-1116
17. Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, Cheng SL: Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 2001, 276:14443-14450
18. Shih I, Wang T, Wu T, Kurman RJ, Gearhart JD: Expression of Mel-CAM in implantation site intermediate trophoblastic cell line, IST-1, limits its migration on uterine smooth muscle cells. J Cell Sci 1998, 111:2655-2664
19. Shih IM, Nesbit M, Herlyn M, Kurman RJ: A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 1998, 11:1098-1106
20. McMaster M, Zhou Y, Shorter S, Kapasi K, Geraghty D, Lim KH, Fisher S: HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation. J Immunol 1998, 160:5922-5928
21. Hsu C-Y, Bristow R, Cha M, Wang BG, Ho C-L, Kurman RJ, Wang T-L, Shih I-M: Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004, 10:6432-6436
22. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR: In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998, 153:1411-1423
23. Gioeli D, Mandell JW, Petroni GR, Frierson Jr HF, Weber MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999, 59:279-284
24. Friedl P, Maaser K, Klein CE, Niggemann B, Krohne G, Zanker KS: Migration of highly aggressive MV3 melanoma cells in 3-dimensional collagen lattices results in local matrix reorganization and shedding of alpha2 and beta1 integrins and CD44. Cancer Res 1997, 57:2061-2070
25. Shih IM, Kurman RJ: Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab Invest 1996, 75:377-388
26. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Kdjana E, Wheelock M, Damsky CH: Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion? J Clin Invest 1997, 99:2139-2151
27. Shih I-M, Hsu MY, Oldt RJ, Herlyn M, Gearhart JD, Kurman RJ: The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. Placenta 2002, 23:706-715
28. Singer G, Kurman RJ, McMaster M, Shih I-M: HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002, 26:914-920
29. Allen LF, Sebolt-Leopold J, Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003, 30:105-116
30. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494
31. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954
32. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63:756-759
33. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS: Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003, 63:5669-5673
34. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-627
35. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934
36. Singer G, Oldt III R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih I-M: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-486
37. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000, 19:6594-6599
38. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, Garcia-Corchon C, Quero C, Soria JC, Martin-Algarra S, Manzano RG, Montuenga LM: ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 2004, 90:1047-1052
39. Pohl G, Ho CL, Kurman RJ, Bristow R, Wang TL, Shih I-M: Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 2005, 65:1994-2000
40. Chou FL, Hill JM, Hsieh JC, Pouyssegur J, Brunet A, Glading A, Uberall F, Ramos JW, Werner MH, Ginsberg MH: PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J Biol Chem 2003, 278:52587-52597
41. Kurata H, Thant AA, Matsuo S, Senga T, Okazaki K, Hotta N, Hamaguchi M: Constitutive activation of MAP kinase kinase (MEK1) is critical and sufficient for the activation of MMP-2. Exp Cell Res 2000, 254:180-188
42. Webb DJ, Nguyen DH, Gonias SL: Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and Matrigel invasion. J Cell Sci 2000, 113:123-134
43. Takino T, Miyamori H, Watanabe Y, Yoshioka K, Seiki M, Sato H: Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration. Cancer Res 2004, 64:1044-1049
44. Tanigawara Y, Kita T, Hirono M, Sakaeda T, Komada F, Okumura K: Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood. Ther Drug Monit 2001, 23:341-346
45. Janneau JL, Maldonado-Estrada J, Tachdjian G, Miran I, Motte N, Saulnier P, Sabourin JC, Cote JF, Simon B, Frydman R, Chaouat G, Bellet D: Transcriptional expression of genes involved in cell invasion and migration by normal and tumoral trophoblast cells. J Clin Endocrinol Metab 2002, 87:5336-5339
46. Zygmunt M, Hahn D, Munstedt K, Bischof P, Lang U: Invasion of cytotrophoblastic JEG-3 cells is stimulated by hCG in vitro. Placenta 1998, 19:587-593
47. Zygmunt M, Hahn D, Kiesenbauer N, Munstedt K, Lang U: Invasion of cytotrophoblastic (JEG-3) cells is up-regulated by interleukin-15 in vitro. Am J Reprod Immunol 1998, 40:326-331